Story · Medicine & Biotech
Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBC
1 outlet · first reported by OncoDaily on
Kamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn: “The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for (OncoDaily)
Coverage, in order
-
Kamel Abou Hussein: Important Milestone in the Evolving Treatment Landscape of HR+/HER2− MBCKamel Abou Hussein, Director of Breast Medical Oncology at MD Anderson Cancer Center at Cooper, shared on LinkedIn: “The FDA has approved giredestrant (Wilserdly) in combination with everolimus (Afinitor) for
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.